

PERFUSE: Non-interventional cohort study of patients receiving infliximab biosimilar SB2; results in paediatric patients

Authors: Christine Martinez-Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill, Janet Addison

Supplementary Table 1. Intensified induction and treatment escalation

		CD (n=102)		UC (n=24)	
		Naive (n=51)	Switched (n=51)	Naive (n=9)	Switched (n=9)
Intensified induction, n (%)	Mean dose in induction period \geq 7 mg/kg	10 (19.6)	32 (62.7)	5 (9.8)	7 (13.7)
	Duration of induction period \leq 5 weeks	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
	Total	10 (19.6)	32 (62.7)	5 (9.8)	7 (13.7)
Intensified treatment between end of induction and M6 visit, n (%)	Mean dose \geq 7 mg/kg	12	33	4	6
	Mean time between injections < 7 weeks	14	22	3	6
	Total	16	36	5	9
Intensified treatment between M6 visit and M12 visit, n (%)	Mean dose \geq 7 mg/kg	19	32	2	7
	Mean time between injections < 7 weeks	13	24	1	5
	Total	22	34	2	8

CD = Crohn's Disease; UC = Ulcerative Colitis